The single-insider purchase by RA Capital (a 10% owner/Director) is a standalone bullish signal per insider-trading literature, though at 0.12% of market cap it is not large enough to force immediate re-rating. Monitor for additional insider buying or a material event filing (pipeline catalyst, partnership, financing) that could explain the concentrated buying. Given ARTV's strong historical long-call win rate (86%), the signal supports a constructive view but does not warrant aggressive positioning.
Price Chart
Executive Summary
RA Capital Management, a 10% owner and director at Artiva Biotherapeutics, purchased ~32.9K shares for $292K over two days. The buying occurs in a strong historical context where previous long calls on ARTV have been highly accurate, though the dollar amount is only ~0.12% of market cap — modest relative to company size.
Key Financial Metrics
Key Facts
- RA Capital Management, a 10% owner/Director, bought 31K shares at $8.88 ($275K) on 6/25 and 1.9K shares at $8.98 ($17K) on 6/26
- Total insider purchase value: $292K
- Purchase represents ~0.12% of $242M market cap
- ARTV has 92% analyst bullish rating (4 Strong Buy, 7 Buy, 1 Hold)
- Historical win rate on prior ARTV long calls: 86% at T+20, with +13.78% average return
Financial Impact
$292K insider purchase, ~0.12% of market cap
Risk Factors
- Purchase value is small relative to market cap (0.12%), limiting signal strength
- Insider buying preceded by strong recent price performance (+35% on prior report) creates potential mean-reversion risk
- Biotech sector binary risk (pipeline failure, financing overhang) independent of insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access